ERBB2 and neoplasm: PTEN expression did not associate with lapatinib response; in patients with HER2-positive tumours (EGF100642, n=36), CBR was not dependent on PTEN (P=0.9093), thus patients with tumours expressing low levels of PTEN derived benefit from lapatinib (Figure 3B).